Azilsartan (medoxomil) - CAS# 863031-21-4 L 13-27 including a full program of

including a full program of reproductive toxicity studies

Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells

InChi: InChI=1S/C20H24O4/c1-13(8-15-4-6-17(21)19(10-15)22-3)14(2)9-16-5-7-18-20(11-16)24-12-23-18/h4-7

GTS-21 bound to human α4β2 nAChR (Ki=20 nM) 100-fold more potently than to humanα7-nAChR

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors

Azilsartan (medoxomil) - CAS# 863031-21-4 L 13-27 including a full program ofAzilsartan medoxomil also known as TAK 491, is an orally administered angiotensin II receptor type 1 antagonist (blocker) used in the treatment of adults with essential hypertension. Azilsartan medoxomil is a useful and attractive new option for lowering BP in patients with essential hypertension, particularly for those not able to tolerate other antihypertensive drugs. Further studies are required to evaluate the effects of azilsartan medoxomil on